Retour sur lavenir.net
   UMICORE 22.420 € (+4,57 %)     SYENSQO 78.000 € (-0,38 %)     EKOPAK 4.040 € (+3,59 %)     KINEPOLIS GROUP 41.100 € (-0,96 %)     ELIA GROUP 129.000 € (+2,79 %)     AZELIS GROUP 11.550 € (+2,48 %)     SHURGARD 25.900 € (+1,57 %)     ONWARD MEDICAL 2.450 € (+4,93 %)     UCB 223.300 € (+0,86 %)     KBC 126.500 € (+0,32 %)     TESSENDERLO 21.450 € (-0,46 %)     CMB.TECH 13.920 € (-1,00 %)     LOTUS BAKERIES 11 080.000 € (-0,72 %)     WDP 22.200 € (+0,45 %)     D'IETEREN GROUP 182.000 € (+1,11 %)     VIOHALCO 18.400 € (+0,55 %)     ONTEX GROUP 2.340 € (+1,52 %)     SIPEF 89.400 € (-0,67 %)     BPOST 1.554 € (+1,57 %)     COLRUYT 38.520 € (-2,08 %)     PROXIMUS 6.320 € (-1,40 %)     NEXTENSA 44.850 € (+0,56 %)     CARE PROPERTY INV. 12.560 € (-0,32 %)     VASTNED 30.000 € (+0,50 %)     ORANGE BELGIUM 22.000 € (0,00 %)     NYXOAH 1.278 € (+2,08 %)     VGP 85.300 € (-0,35 %)     WERELDHAVE BELGIUM 53.200 € (0,00 %)     SOLVAY 26.520 € (-0,23 %)     SOLVAC NOM(RETAIL) 80.000 € (+0,63 %)     MELEXIS 70.850 € (+2,83 %)     GIMV 45.150 € (0,00 %)     VAN DE VELDE 29.900 € (-0,33 %)     OPTION 3.900 € (0,00 %)     XIOR 27.650 € (0,00 %)     AGFA-GEVAERT 0.380 € (-2,56 %)     ABO GROUP 3.880 € (+0,52 %)     BEKAERT 39.350 € (+0,77 %)     BIOTALYS 2.680 € (+4,69 %)     DEME GROUP 167.000 € (+0,97 %)     GBL 79.500 € (+0,63 %)     TUBIZE-FIN 194.100 € (+0,88 %)     CENERGY 23.180 € (+4,98 %)     EVS 28.300 € (+2,54 %)     AB INBEV 73.200 € (-0,38 %)     TINC 11.460 € (-0,35 %)     BREDERODE 102.800 € (-0,19 %)     CIE BOIS SAUVAGE 301.000 € (-0,99 %)     SOFINA 250.600 € (+0,97 %)     AEDIFICA 69.850 € (+0,50 %)     KBC ANCORA 89.700 € (+0,34 %)     CAMPINE 208.000 € (+0,48 %)     TITAN S.A. 54.000 € (+2,08 %)     IBA 16.100 € (+1,00 %)     BARCO 8.020 € (+1,71 %)     HOME INVEST BE. 20.050 € (-0,50 %)     ENERGYVISION 15.420 € (+1,18 %)     ATENOR 1.510 € (-0,66 %)     MONTEA 68.000 € (+0,29 %)     FAGRON 22.250 € (-1,55 %)  
   2CRSI 25.540 € (+4,07 %)     DASSAULT SYSTEMES 21.310 € (+2,70 %)     WOLTERS KLUWER 71.600 € (+2,84 %)     RELX 31.640 € (+1,87 %)     SCHNEIDER ELECTRIC 299.250 € (+3,15 %)     ASM INTERNATIONAL 810.800 € (+1,96 %)     LVMH 485.000 € (-0,39 %)     WINAMP GROUP 0.380 € (-6,17 %)     LLAMA GROUP 0.380 € (-6,17 %)     BE SEMICONDUCTOR 217.700 € (+8,09 %)     AIR FRANCE -KLM 12.565 € (+0,96 %)     ABN AMRO BANK N.V. 39.840 € (+1,04 %)     AEGON 8.236 € (-0,05 %)     REXEL 37.130 € (+1,98 %)     COVIVIO 53.050 € (-0,66 %)     EUROFINS SCIENT. 68.820 € (+1,59 %)     ICADE 19.510 € (-0,46 %)     AMG 29.780 € (+3,33 %)     ING GROEP N.V. 30.670 € (+1,27 %)     AXA 44.630 € (0,00 %)     AMUNDI 96.600 € (-0,05 %)     MAUREL ET PROM 7.920 € (-2,04 %)     PHILIPS KON 22.880 € (+0,75 %)     AKZO NOBEL 62.920 € (+2,24 %)     ALSTOM 16.840 € (+1,78 %)     PRECIA 25.500 € (-2,67 %)     SOITEC 120.100 € (+9,88 %)     LOUIS HACHETTE 1.810 € (+1,17 %)     SCOR SE 34.080 € (-0,18 %)     BNP PARIBAS ACT.A 111.880 € (+0,09 %)     THALES 262.400 € (+3,39 %)     ADUX 1.200 € (-4,00 %)     BUREAU VERITAS 28.630 € (+1,35 %)     SOLUTIONS 30 SE 0.603 € (+6,35 %)     DASSAULT AVIATION 310.200 € (+1,77 %)     ABIVAX 108.700 € (+1,30 %)     LISI 66.300 € (+3,27 %)     WORLDLINE 13.512 € (+0,37 %)     ALTAREA 101.000 € (+0,20 %)     SAINT GOBAIN 84.920 € (+1,68 %)     ENOGIA 6.640 € (-0,60 %)     ADYEN 938.400 € (+3,33 %)     KAUFMAN ET BROAD 25.450 € (-0,20 %)     ASML HOLDING 1 472.600 € (+3,73 %)     SAFRAN 356.400 € (+1,45 %)     TotalEnergiesGabon 213.500 € (-0,70 %)     APERAM 47.120 € (+1,51 %)     AIRBUS 214.100 € (+2,93 %)     MAGNUM 15.942 € (-0,75 %)     LHYFE 2.010 € (-1,95 %)     PHARMING GROUP 0.905 € (+2,47 %)     SOCIETE GENERALE 83.000 € (-0,11 %)     VOPAK 48.020 € (-1,96 %)     AALBERTS NV 44.220 € (+1,66 %)     SHELL PLC 38.875 € (-2,34 %)     ALFEN 12.760 € (+1,11 %)     CEGEDIM 10.480 € (-0,19 %)     CARREFOUR 15.735 € (-0,79 %)     ENGIE 26.820 € (-0,19 %)     TELEPERFORMANCE 67.040 € (+3,20 %)  
News Réglementées
04/08/2026 14:05

Revolune Announces Service Provider Program with CellCarta, Concept Life Sciences, and Propath UK

EQS-News: Revolune / Key word(s): Joint Venture/Agreement
Revolune Announces Service Provider Program with CellCarta, Concept Life Sciences, and Propath UK

04.08.2026 / 14:05 CET/CEST
The issuer is solely responsible for the content of this announcement.


OBERKOCHEN, Germany, Aug. 4, 2026 /PRNewswire/ -- Revolune today announced the launch of its Service Provider Program, a new partner model designed to expand customer access to Revolune-powered multiplex immunofluorescence (mIF) workflows through experienced service laboratories. The program launches with CellCarta, Concept Life Sciences, and Propath UK as participating service providers, giving researchers and translational teams multiple routes to evaluate, adopt, and scale flexible multiplex staining workflows.

Revolune Service Providers

The Revolune Service Provider Program is designed for customers who want access to advanced multiplex IF capabilities but may not yet have the infrastructure, capacity, or internal expertise to run every step of the workflow in-house. Through the program, customers can work with qualified service providers to support panel design, staining execution, imaging, and downstream analysis while maintaining access to Revolune's adaptable multiplex staining technology.

"Many customers are looking for more flexible approaches to multiplex IF, but they need practical ways to get started," said Florian Leiss, CEO of Revolune. "By launching our Service Provider Program with CellCarta, Concept Life Sciences, and Propath UK, we are giving customers trusted routes to access Revolune-powered workflows — whether they want to outsource execution, build capabilities internally, or combine both approaches."

The program comes as researchers, translational teams, and biopharma organizations evaluate new options for tissue-based biomarker discovery and development. Revolune's technology is designed to support customizable multiplex staining workflows that can adapt to changing research questions, sample types, and translational needs. By working with service providers that bring experience in tissue-based research, biomarker services, and complex assay execution, Revolune aims to make adoption faster and more practical for a broader range of customers.

Each partner brings complementary strengths. CellCarta delivers global precision medicine laboratory capabilities, backed by deep histopathology expertise alongside genomics, proteomics, and immunology. Our teams support analysis at any stage, spanning biomarker discovery through CDx development. Benefit from our global network of pathologists and validated singleplex, multiplex and hyperplex assays.

Concept Life Sciences provides expert discovery, development, analytical, and specialist laboratory services across the life sciences sector.

Propath UK offers specialist spatial biology and tissue-based biomarker services, including experience supporting complex multiplex proteomic and transcriptomic workflows.

The launch of the Service Provider Program marks an important step in Revolune's broader commercial strategy. In addition to offering technology directly to customers, Revolune will continue building a partner ecosystem that supports adoption through service-based execution, application expertise, and workflow support.

About Revolune

Revolune develops flexible multiplex staining technologies designed to make advanced tissue biomarker workflows more accessible, adaptable, and practical for research and translational applications.

About CellCarta

CellCarta is a global CRO supporting biopharma with reliable, regulatory-ready biomarker data from translational research to CDx. With fully owned and harmonized laboratory operations across North America, Europe, Australia, and China, CellCarta delivers integrated capabilities spanning immunology, histopathology, proteomics, and genomics, supported by comprehensive sample management and logistics solutions.

About Concept Life Sciences

Concept Life Sciences is a leading contract research organisation (CRO) serving the global life sciences industry. The company offers sophisticated spatial and translational biology services, biomarker discovery and development capabilities, and exceptional end-to-end chemistry expertise to support drug discovery and development programs.

About Propath UK

Propath UK — The Spatial Biology CRO® — delivers the expertise, quality, and scientific partnership needed to transform complex tissue samples into meaningful biological insight.

Contact
hello@revolune.com 

Revolune Logo

Cision View original content to download multimedia:https://www.prnewswire.co.uk/news-releases/revolune-announces-service-provider-program-with-cellcarta-concept-life-sciences-and-propath-uk-302841211.html

rt.gif?NewsItemId=EN17621&Transmission_Id=202608040800PR_NEWS_EURO_ND__EN17621&DateId=20260804


04.08.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2377090  04.08.2026 CET/CEST

Source : Webdisclosure.com

© 2026 Tous droits réservés
Cotations différées d'au moins 15 minutes (Paris, Amsterdam, Bruxelles, Lisbonne).
Cotations à la clôture (Francfort, New-York, Londres, Zurich).
Flux de cotations : Euronext (Places Euronext et Cours des Devises).
Bourse : technologie Cote Boursière